home / stock / janx / janx quote
Last: | $47.10 |
---|---|
Change Percent: | -0.53% |
Open: | $47.76 |
Close: | $47.10 |
High: | $47.97 |
Low: | $46.79 |
Volume: | 669,086 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$47.1 | $47.76 | $47.1 | $47.97 | $46.79 | 669,086 | 05-17-2024 |
$47.51 | $47.18 | $47.51 | $48.25 | $46.5701 | 680,511 | 05-16-2024 |
$47.48 | $49.22 | $47.48 | $49.87 | $47.34 | 918,537 | 05-15-2024 |
$47.91 | $50.9 | $47.91 | $51.33 | $47.51 | 690,722 | 05-14-2024 |
$49.99 | $50 | $49.99 | $50.075 | $47.915 | 864,250 | 05-13-2024 |
$48.92 | $52.92 | $48.92 | $53.54 | $48.54 | 1,031,669 | 05-10-2024 |
$51.94 | $54 | $51.94 | $54.91 | $50.79 | 1,492,791 | 05-09-2024 |
$55.37 | $53.68 | $55.37 | $58 | $51.63 | 1,544,960 | 05-08-2024 |
$61.5 | $62.67 | $61.5 | $63.3743 | $60.39 | 518,330 | 05-07-2024 |
$62.19 | $63.16 | $62.19 | $63.34 | $57.11 | 868,310 | 05-06-2024 |
$64.78 | $63.98 | $64.78 | $65.6 | $59.3101 | 1,049,929 | 05-03-2024 |
$62.43 | $59.94 | $62.43 | $64.79 | $56.41 | 1,118,091 | 05-02-2024 |
$58.19 | $57 | $58.19 | $60.05 | $55.53 | 906,265 | 05-01-2024 |
$57 | $54.88 | $57 | $57.11 | $53.6 | 653,594 | 04-30-2024 |
$56.08 | $47.85 | $56.08 | $61 | $47.58 | 1,537,542 | 04-29-2024 |
$47.39 | $47.08 | $47.39 | $48.23 | $46.51 | 573,989 | 04-26-2024 |
$47.1 | $48.3 | $47.1 | $48.3 | $45.68 | 555,331 | 04-25-2024 |
$48.21 | $49.95 | $48.21 | $50.06 | $46.52 | 580,038 | 04-24-2024 |
$49.78 | $49.31 | $49.78 | $50.42 | $48.28 | 706,606 | 04-23-2024 |
$48.88 | $49.66 | $48.88 | $49.95 | $44.71 | 1,119,218 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
2024-05-13 10:30:04 ET Wedbush analyst issues BUY recommendation for JANX on May 13, 2024 09:00AM ET. The previous analyst recommendation was Buy. JANX was trading at $49.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $651.8 million in cash and cash equivalents and short-term...
2024-04-30 00:06:00 ET Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.4...